Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5705)
All Articles published online
|
Feb 28, 2013 (publication date) through Feb 3, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Koutsounas I, Giaginis C, Theocharis S. Histone deacetylase inhibitors and pancreatic cancer: Are there any promising clinical trials? World J Gastroenterol 2013; 19(8): 1173-1181 [PMID: 23482354 DOI: 10.3748/wjg.v19.i8.1173] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i8/1173.htm |
| Number | Citing Articles |
| 1 |
Monika Bauden, Helena Tassidis, Daniel Ansari. In vitro cytotoxicity evaluation of HDAC inhibitor Apicidin in pancreatic carcinoma cells subsequent time and dose dependent treatment. Toxicology Letters 2015; 236(1): 8 doi: 10.1016/j.toxlet.2015.03.017
|
| 2 |
Chang‐Il Hwang, Sylvia F Boj, Hans Clevers, David A Tuveson. Preclinical models of pancreatic ductal adenocarcinoma. The Journal of Pathology 2016; 238(2): 197 doi: 10.1002/path.4651
|
| 3 |
Hui Zhang, Yu‐Ping Shang, Hong‐ying Chen, Jun Li. Histone deacetylases function as novel potential therapeutic targets for cancer. Hepatology Research 2017; 47(2): 149 doi: 10.1111/hepr.12757
|
| 4 |
Takehiro Ogata, Mizuyo Nakamura, Meijie Sang, Hiroyuki Yoda, Kiriko Hiraoka, Danjing Yin, Mexiang Sang, Osamu Shimozato, Toshinori Ozaki, Thomas G. Hofmann. Depletion of runt-related transcription factor 2 (RUNX2) enhances SAHA sensitivity of p53-mutated pancreatic cancer cells through the regulation of mutant p53 and TAp63. PLOS ONE 2017; 12(7): e0179884 doi: 10.1371/journal.pone.0179884
|
| 5 |
Vivek Kumar Mishra, Florian Wegwitz, Robyn Laura Kosinsky, Madhobi Sen, Roland Baumgartner, Tanja Wulff, Jens T. Siveke, Hans-Ulrich Schildhaus, Zeynab Najafova, Vijayalakshmi Kari, Hella Kohlhof, Elisabeth Hessmann, Steven A. Johnsen. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner. Nucleic Acids Research 2017; 45(11): 6334 doi: 10.1093/nar/gkx212
|
| 6 |
Sonja Mertsch, Solon Thanos. HDAC/HAT Function Assessment and Inhibitor Development. Methods in Molecular Biology 2017; 1510: 61 doi: 10.1007/978-1-4939-6527-4_5
|
| 7 |
Mao-Hua Cai, Xiao-Gang Xu, Shi-Li Yan, Ze Sun, Yin Ying, Bai-Kui Wang, Yue-Xing Tu. Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-20004-0
|
| 8 |
Hanieh Jafary, Shahin Ahmadian, Masoud Soleimani. The enhanced apoptosis and antiproliferative response to combined treatment with valproate and nicotinamide in MCF-7 breast cancer cells. Tumor Biology 2014; 35(3): 2701 doi: 10.1007/s13277-013-1356-0
|
| 9 |
Magdalena Kusaczuk, Rafał Krętowski, Marek Bartoszewicz, Marzanna Cechowska-Pasko. Phenylbutyrate—a pan-HDAC inhibitor—suppresses proliferation of glioblastoma LN-229 cell line. Tumor Biology 2016; 37(1): 931 doi: 10.1007/s13277-015-3781-8
|
| 10 |
Suk-Youl Park, Jeong-Sun Kim. A short guide to histone deacetylases including recent progress on class II enzymes. Experimental & Molecular Medicine 2020; 52(2): 204 doi: 10.1038/s12276-020-0382-4
|
| 11 |
Yongji Zeng, Ling Yin, Jiuli Zhou, Renya Zeng, Yi Xiao, Adrian R. Black, Tuo Hu, Pankaj K. Singh, Feng Yin, Surinder K. Batra, Fang Yu, Yuanhong Chen, Jixin Dong. MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer. Oncogene 2022; 41(31): 3859 doi: 10.1038/s41388-022-02399-3
|
| 12 |
Han‐Yu Cao, Ling Li, Sheng‐Li Xue, Hai‐Ping Dai. Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy. Hematological Oncology 2023; 41(3): 301 doi: 10.1002/hon.3088
|
| 13 |
Xiaoyu Yang, Yi Xu, Tao Wang, Dan Shu, Peixuan Guo, Keith Miskimins, Steven Y. Qian. Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells. Redox Biology 2017; 11: 653 doi: 10.1016/j.redox.2017.01.016
|
| 14 |
James RW Conway, David Herrmann, TR Jeffry Evans, Jennifer P Morton, Paul Timpson. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut 2019; 68(4): 742 doi: 10.1136/gutjnl-2018-316822
|
| 15 |
Wesley R Samore, Christopher S Gondi. Brief overview of selected approaches in targeting pancreatic adenocarcinoma. Expert Opinion on Investigational Drugs 2014; 23(6): 793 doi: 10.1517/13543784.2014.902933
|
| 16 |
Tomas Koltai, Stephan Joel Reshkin, Tiago M. A. Carvalho, Daria Di Molfetta, Maria Raffaella Greco, Khalid Omer Alfarouk, Rosa Angela Cardone. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Cancers 2022; 14(10): 2486 doi: 10.3390/cancers14102486
|
| 17 |
Hanieh Jafary, Shahin Ahmadian, Masoud Soleimani. Synergistic anticancer activity of valproate combined with nicotinamide enhances anti-proliferation response and apoptosis in MIAPaca2 cells. Molecular Biology Reports 2014; 41(6): 3801 doi: 10.1007/s11033-014-3246-y
|
| 18 |
Wan Feng, Bin Zhang, Dawei Cai, Xiaoping Zou. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. Cancer Letters 2014; 347(2): 183 doi: 10.1016/j.canlet.2014.02.012
|
| 19 |
Shrey Modi, Devika Kir, Sulagna Banerjee, Ashok Saluja. Control of Apoptosis in Treatment and Biology of Pancreatic Cancer. Journal of Cellular Biochemistry 2016; 117(2): 279 doi: 10.1002/jcb.25284
|
| 20 |
Xue-Song Xiang, Peng-Cheng Li, Wen-Quan Wang, Liang Liu. Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2022; 1877(1): 188676 doi: 10.1016/j.bbcan.2022.188676
|
| 21 |
Nikolaos Garmpis, Christos Damaskos, Anna Garmpi, Serena Valsami, Dimitrios Dimitroulis. Pharmacoepigenetics. 2019; : 501 doi: 10.1016/B978-0-12-813939-4.00013-9
|
| 22 |
Shang Minjie, Hong Defei, Hu Zhimin, Wu Weiding, Zhang Yuhua. Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595. Tumor Biology 2015; 36(11): 9015 doi: 10.1007/s13277-015-3537-5
|
| 23 |
Constantinos Giaginis, Christos Damaskos, Ioannis Koutsounas, Adamantia Zizi-Serbetzoglou, Nicolaos Tsoukalas, Efstratios Patsouris, Gregorios Kouraklis, Stamatios Theocharis. Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival. BMC Gastroenterology 2015; 15(1) doi: 10.1186/s12876-015-0379-y
|
| 24 |
Prasad Dandawate, Dharmalingam Subramaniam, Shrikant Anant. Food Toxicology. 2016; : 433 doi: 10.1201/9781315371443-23
|
| 25 |
Simmi Sharma, Mudassier Ahmad, Javeed Ahmad Bhat, Arvind Kumar, Manjeet Kumar, Mohmmad Afzal Zargar, Abid Hamid, Bhahwal Ali Shah. Design, synthesis and biological evaluation of β-boswellic acid based HDAC inhibitors as inducers of cancer cell death. Bioorganic & Medicinal Chemistry Letters 2014; 24(19): 4729 doi: 10.1016/j.bmcl.2014.08.007
|
| 26 |
Rupali Sharma, Bhargav Earla, Kwamena E. Baidoo, Martha A. Zeiger, James P. Madigan, Freddy E. Escorcia, Samira M. Sadowski. Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model. Molecular Cancer Therapeutics 2023; 22(9): 1052 doi: 10.1158/1535-7163.MCT-22-0798
|
| 27 |
Dimitrios Schizas, Aikaterini Mastoraki, Leon Naar, Eleftherios Spartalis, Diamantis I Tsilimigras, Georgia-Sofia Karachaliou, George Bagias, Dimitrios Moris. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment. World Journal of Gastroenterology 2018; 24(41): 4635-4642 doi: 10.3748/wjg.v24.i41.4635
|
| 28 |
Megan E. Kondash, Anandita Ananthakumar, Alastair Khodabukus, Nenad Bursac, George A. Truskey. Glucose Uptake and Insulin Response in Tissue-engineered Human Skeletal Muscle. Tissue Engineering and Regenerative Medicine 2020; 17(6): 801 doi: 10.1007/s13770-020-00242-y
|
| 29 |
Geoffrey Kozak, Fernando F. Blanco, Jonathan R. Brody. Novel Targets in Pancreatic Cancer Research. Seminars in Oncology 2015; 42(1): 177 doi: 10.1053/j.seminoncol.2014.12.015
|
| 30 |
Feng Jiao, Hai Hu, Ting Han, Meng Zhuo, Cuncun Yuan, Haiyan Yang, Lei Wang, Liwei Wang. Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer. Oncotarget 2016; 7(13): 16505 doi: 10.18632/oncotarget.7663
|
| 31 |
Dharmalingam Subramaniam, Ravi Thombre, Animesh Dhar, Shrikant Anant. DNA Methyltransferases: A Novel Target for Prevention and Therapy. Frontiers in Oncology 2014; 4 doi: 10.3389/fonc.2014.00080
|
| 32 |
Heidy Martínez-Pacheco, Ofir Picazo, Adolfo López-Torres, Jean-Pascal Morin, Karla Viridiana Castro-Cerritos, Rossana Citlali Zepeda, Gabriel Roldán-Roldán. Biochemical and Behavioral Characterization of IN14, a New Inhibitor of HDACs with Antidepressant-Like Properties. Biomolecules 2020; 10(2): 299 doi: 10.3390/biom10020299
|
| 33 |
Andrew H. Nguyen, Irmina A. Elliott, Nanping Wu, Cynthia Matsumura, Maria Vogelauer, Narsis Attar, Amanda Dann, Razmik Ghukasyan, Paul A. Toste, Sanjeet G. Patel, Jennifer L. Williams, Luyi Li, David W. Dawson, Caius Radu, Siavash K. Kurdistani, Timothy R. Donahue. Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts. Oncotarget 2017; 8(12): 19074 doi: 10.18632/oncotarget.13572
|
| 34 |
Zdeněk Kejík, Milan Jakubek, Robert Kaplánek, Jarmila Králová, Ivan Mikula, Pavel Martásek, Vladimír Král. Epigenetic Agents in Combined Anticancer Therapy. Future Medicinal Chemistry 2018; 10(9): 1113 doi: 10.4155/fmc-2017-0203
|
| 35 |
Seong-Jun Park, Sang Hoon Joo, Naeun Lee, Won-Jun Jang, Ji Hae Seo, Chul-Ho Jeong. ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy. Archives of Pharmacal Research 2021; 44(12): 1062 doi: 10.1007/s12272-021-01359-x
|
| 36 |
Richard S. Laschanzky, Lisa E. Humphrey, Jihyun Ma, Lynette M. Smith, Thomas J. Enke, Surendra K. Shukla, Aneesha Dasgupta, Pankaj K. Singh, Gillian M. Howell, Michael G. Brattain, Quan P. Ly, Adrian R. Black, Jennifer D. Black. Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy. Cancers 2019; 11(9): 1327 doi: 10.3390/cancers11091327
|
| 37 |
Jason Tasoulas, Constantinos Giaginis, Efstratios Patsouris, Evangelos Manolis, Stamatios Theocharis. Histone deacetylase inhibitors in oral squamous cell carcinoma treatment. Expert Opinion on Investigational Drugs 2015; 24(1): 69 doi: 10.1517/13543784.2014.952368
|
| 38 |
Weiwei Fan, Xijia Yang, Liang Zhou, Jianqing Xu, Weihua Huang, Alok Shiomurti Tripathi. 5HT2A modulation attenuates pancreatic cancer induced pain mouse model by inhibiting HDAC. Acta Cirúrgica Brasileira 2024; 39 doi: 10.1590/acb392324
|
| 39 |
Forogh Adhami, Maliheh Safavi, Maryam Ehsani, Sussan K. Ardestani, Franziska Emmerling, Farzaneh Simyari. Synthesis, crystal structure, and cytotoxic activity of novel cyclic systems in [1,2,4]thiadiazolo[2,3-a]pyridine benzamide derivatives and their copper(ii) complexes. Dalton Trans. 2014; 43(21): 7945 doi: 10.1039/C3DT52905C
|
| 40 |
Jasmijn G.M. van Kampen, Monica A.J. Marijnissen-van Zanten, Femke Simmer, Winette T.A. van der Graaf, Marjolijn J.L. Ligtenberg, Iris D. Nagtegaal. Epigenetic targeting in pancreatic cancer. Cancer Treatment Reviews 2014; 40(5): 656 doi: 10.1016/j.ctrv.2013.12.002
|
| 41 |
Alexander Arlt, Heiner Schäfer. Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma. Expert Opinion on Investigational Drugs 2016; 25(11): 1251 doi: 10.1080/13543784.2016.1240167
|